Multicenter randomized placebo controlled trial of therapy with intravenous immunoglobulin in decreasing mortality due to neonatal sepsis.
OBJECTIVE
To determine whether therapy with intravenous immunoglobulin G (IVIG) would decrease mortality in neonatal sepsis.


METHODS
Three tertiary care neonatal intensive care units in the city of Bangalore.


METHODS
All neonates admitted to the Neonatal Intensive Care Units with the clinical diagnosis of sepsis and having at least C-reactive protein and one other rapid diagnostic criteria positive were enrolled. Neonates with a birth weight of less than 1000 g and those with any major congenital malformation were excluded. The neonates were randomized to receive 1 g/kg of IVIG on three consecutive days or an equivalent amount of placebo. The rest of the treatment including antibiotics and supportive care was as per the treating physician's decision. The main outcome variable was survival.


RESULTS
The trial was carried out over a period of 8 months and recruited 58 neonates. Seven neonates who qualified but did not receive either IVIG or placebo were taken into a separate control group, and one baby who received only one dose of IVIG was excluded from the analysis. Twenty-five neonates were enrolled into the IVIG arm and 25 in the placebo arm. The neonates in the therapy and placebo groups were comparable in terms of birth weight (2144+/-675 g vs. 2072+/-682 g), gestation (37.0+/-3.56 vs. 35.8+/-3.52 weeks), sex distribution, duration of stay, and number requiring ventilation. The placebo group had a significantly higher number of babies with positive blood culture. Seven babies in each group died (p>0.05). There was no significant benefit in using IVIG (OR 1.0; 95% CI 0.25-4.07) (p = 0.74).


CONCLUSIONS
In the sample studied therapy with IVIG did not reduce mortality in neonatal sepsis
Shenoi
A
A
Department of Neonatology and Pediatrics, Manipal Hospital, Bangalore, India. perinatal@vsnl.com
Nagesh
N K
NK
Maiya
P P
PP
Bhat
S R
SR
Subba Rao
S D
SD
D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007194:India; D007231:Infant, Newborn; D008297:Male; D018805:Sepsis / Q000188:drug therapy* / Q000276:immunology; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous